Novartis announced that the FDA has accepted the company’s supplemental New Drug Application, or sNDA, and granted Priority Review designation to Promacta in combination with standard immunosuppressive therapy, or IST, for first-line treatment of severe aplastic anemia, or SAA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.